Next Article in Journal
RNA-Based Next-Generation Sequencing in the Somatic Molecular Testing of Non-Small-Cell Lung Cancer (NSCLC) in a Centralized Model: Real-World Data to Suggest It Is Time to Reconsider Testing Options
Next Article in Special Issue
Optimal Assessment of Metastatic Breast Carcinoma: The Value of Cytopathology Combined with Molecular Analysis
Previous Article in Journal
Langerhans Cell Histiocytosis-Associated Pulmonary Adenocarcinoma: A Word of Caution during Molecular Determinations
Previous Article in Special Issue
The Value of Fine Needle Aspiration Biopsy in the Pre-Operative Assessment of the Axilla in Breast Cancer Patients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMP
Volume 3
Issue 4
10.3390/jmp3040025
Review Report
jmp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Comprehensive Review of Metastatic Breast Carcinoma in Cytology Specimens

J. Mol. Pathol. 2022, 3(4), 293-306; https://doi.org/10.3390/jmp3040025
by Swikrity U. Baskota 1, Daniel Qazi 2, Ashish Chandra 3 and Poonam Vohra 2,*
Reviewer 1:
Malini Harigopal
J. Mol. Pathol. 2022, 3(4), 293-306; https://doi.org/10.3390/jmp3040025
Submission received: 29 September 2022 / Revised: 21 October 2022 / Accepted: 23 October 2022 / Published: 7 November 2022
(This article belongs to the Special Issue The Cytopathology of Metastatic Breast Cancer)

Round 1

Reviewer 1 Report

This is a timely review with practical implications.

The authors have described the morphological features of the IDC and ILC at metastatic sites in this brief review with good detail. However, it would also be interesting to the readers to understand how the work up the of the metastatic cancers using the appropriate ancillary IHC stains. In triple negative breast cancers the addition of TRPS1 to the existing panel of breast markers (Gata 3, mammaglobub, GCDFP-15)  has helped confirm breast origin. In order to make this review more comprehensive and complete I suggest adding a paragraph on the IHC work up.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

First, I would like to thank you for inviting me to review this interesting manuscript.

 

The authors present a comprehensive review of metastatic breast carcinoma in cytology specimens. The manuscript is well written in terms of clarity, style, and use of English and has a logical construction. The figures are of good quality. The references are appropriate and current.

 

Minor issues

1) Isolated tumor cells are < 200 cells or less than 0,2mm

2) Invasive ductal carcinoma should be substituted with invasive breast carcinoma of no special type

 3) The authors review the findings of invasive carcinoma of NST and invasive lobular carcinoma. Are there any specific cytological findings in other special types of carcinoma (mucinous or micropapillary type carcinoma for example)?

4) The authors mention that: “In our clinical practice, irrespective of the specimen type and sites, a strong GATA-3 positivity with the positivity of at least one other breast markers (GCDFP15, mammaglobin) or breast biomarkers (ER, PR, and HER-2) is sufficient to diagnose MBC.” I agree that this is true in almost all cases. One possible exception would be metastatic micropapillary urothelial carcinoma which is almost always GATA-3 and very often HER-2 positive.  

 

5) The authors mention that “pleomorphic lobular carcinoma can show apocrine features which can cause nonspecific IHC positivity that may lead to diagnostic pitfall.” Please be more specific. Which antibody/antibodies? 

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Back to TopTop